Apoptosis targeted therapies in acute myeloid leukemia: an update.

Expert Review of Hematology
Somedeb Ball, Gautam Borthakur

Abstract

Introduction: Management of acute myeloid leukemia (AML) continues to be a therapeutic challenge despite significant recent advancements. Dysregulation of several components of apoptotic pathways has been identified as potential driver in AML. Areas covered: Overexpression of anti-apoptotic proteins, B-cell lymphoma 2 (BCL2), BCL-XL, and myeloid cell leukemia-1 (MCL1), has been associated with worse outcome in AML. Dysfunction of p53 pathway (often through mouse double minute 2 homolog (MDM2)) and high expression of inhibitor of apoptosis proteins (IAP) constitute other disruptions of apoptotic machinery. Significant antileukemic activity of BCL2 inhibitors (particularly venetoclax) in preclinical models has translated into improved objective response and overall survival in combination with hypomethylating agents in AML. Addition of MCL1, BCL-XL, or MDM2 inhibitors could potentially overcome resistance to BCL2 inhibition. Authors conducted a thorough review of available literature on therapeutic options targeting apoptosis in AML, using PubMed, MEDLINE, meeting abstracts, and ClinicalTrials.gov. Expert opinion: While venetoclax remains the core component of targeting apoptosis, ongoing clinical trials should help find ideal co...Continue Reading

References

Nov 26, 1996·Proceedings of the National Academy of Sciences of the United States of America·L KlampferS D Nimer
Dec 14, 1999·The Journal of Biological Chemistry·M Oren
Feb 24, 2005·Cancer Biology & Therapy·Zhaoyu Jin, Wafik S El-Deiry
May 3, 2008·Cancer Research·Christin TseSteven W Elmore
Jun 24, 2008·Molecular Cancer Research : MCR·Juan A BarbozaGuillermina Lozano
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aaron D SchimmerMichael Andreeff
Mar 2, 2010·Cancer Biology & Therapy·Brian Leibowitz, Jian Yu
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Apr 23, 2013·Molecular Cancer Research : MCR·Sandrine EttouMichaela Fontenay
Jun 22, 2013·Genes & Development·Robert L ThomasÅsa B Gustafsson
Feb 15, 2014·Journal of the National Cancer Institute·Bing Z CarterMichael Andreeff
Mar 12, 2015·Cancer Cell·Elodie Pronier, Ross L Levine
Jun 27, 2015·Seminars in Hematology·Andreas ReinischRavindra Majeti
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Feb 1, 2017·Leukemia & Lymphoma·Prithviraj BoseMarina Konopleva
Sep 9, 2017·Cell·Edward R Kastenhuber, Scott W Lowe

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.